2024 draws to a close, we look back on the precious moments of joy we experienced as well as the significant challenges we all faced. It has been a year of highs and lows that have both shaped and strengthened us.

The new paper by Japanese researchers from the University of Tokyo, recently published in Nature - Scientific Reports is entitled “Win Ratio Analysis of Short-Term Clinical Outcomes of Focal Therapy and Robot-Assisted Radical Prostatectomy for Patients with Localized Prostate Cancer” and compares focal therapy, specifically Sonablate HIFU, with robot-assisted radical prostatectomy (RARP) for localized prostate cancer.

The Focal Ablation Surgery for Selective Tumors (FASST) trial is a significant multinational study investigating the efficacy and safety of focal high-intensity focused ultrasound (HIFU) as a treatment for localized, low-to-intermediate-risk prostate cancer.

Gold Anchor MR+ is used for MR-only workflows in prostate SBRT treatments at Tampere University Hospital in Finland.

Single-use ureteroscopes have become increasingly important in modern endourology, especially the 7.5 FR disposable ureteroscope. These instruments were specially developed for the treatment of ureteral diseases and offer numerous advantages over reusable models, but also over the standard 9.2 FR ureteroscopes.

The year 2023 is almost over, with many beautiful but also difficult moments. It has made us realise once again how fragile our world is and how dependent we all are on each other.

The International Day of Charity was established with the objective of sensitizing and mobilizing people, NGOs, and stakeholders all around the world to to help others through volunteer and philanthropic activities. The date of 5 September was chosen in order to commemorate the anniversary of the passing away of Mother Teresa of Calcutta.

Treatment for high-risk non–muscle-invasive bladder cancer (NMIBC) with hyperthermic intravesical Switzerland has reached another noteworthy milestone in the field of innovative and research-based medicine. As of July 1, 2023, health insurance coverage will be extended to include focal HIFU therapy for localized prostate carcinoma. This marks a significant step forward in providing comprehensive and advanced healthcare services for patients in the country.

The use of healthcare services accounts for more than five percent of Switzerland's consumption-related greenhouse gas emissions.

The Gold Anchor, our innovative fiducial marker, has been placed endoscopically by many leading university hospitals in rectal, pancreatic, esophageal, and central lung tumors.

May the new year be filled with health, happiness, prosperity, hope and peace! Your innoMedicus.

Promising results regarding the treatment of high-risk non-muscle-invasive bladder cancer (HR- NMIBC) patients with recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) as an alternative to intravesical bacillus Calmette–Guérin (BCG) were recently published in the World Journal of Urology.

Encouraging results of long-term cancer control data from the longest study of focal HIFU treatment was recently publishes in European Urology.

Impressive results regarding long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) using Combat BRS for BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) patients was recently published in Urologic Oncology.

As 2021 comes to an end, this is our time to say thank you.

The film by Swiss-Indian filmmaker Kamal Musale is a contemporary drama and an epic biopic about Mother Teresa, which inspires to look at one's own values and to live compassion, respect and love in one's personal environment. A captivating movie that we at innoMedicus encourage you to watch.

Encouraging results of the world’s largest propensity matched comparison of salvage robot-assisted radical prostatectomy (RARP) after focal and whole gland nonsurgical primary therapy from the UK group has been published in the European Urology Open Science.

Treatment for high-risk non–muscle-invasive bladder cancer (NMIBC) with hyperthermic intravesical chemotherapy (HIVEC) using high-dose mitomycin-C (MMC) is safe, well tolerated, and appears efficacious after short-term follow-up, according to a report from Duke University urologists, which has been published in Urologic Oncology.

The first study to compare bi-parametric MRI, ultrasound and PSA as a screening test for prostate cancer has been recently published in JAMA Oncology.

The publication at The Journal of Urology entitled “High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series” details the study of 100 men with biopsy-confirmed prostate cancer, 72% of which were classified with intermediate or high-risk disease.

This year was a very challenging year for all of us. All the more we would like to thank you for your loyalty and for believing in us.

After the tremendous success of the FOCAL2019 in Miami, the annual conference on the Frontiers in Oncologic Prostate Care and Ablative Local Therapy FOCAL2020 took place virtually where a lot of participants from the world over attended this cutting-edge meeting despite Covid-19 restrictions.

mpMRI has dramatically changed how urologists diagnose and monitor prostate cancer, as it not only allows lesions to be targeted in biopsies but also helps in deciding which patients to biopsy.

Promising preliminary results from HIVEC-HR randomized trial with 24 months of median follow-up, presented by a group of urologists from the Hospital Universitario 12 de Octubre, Madrid, peaked great interest at AUA 2020, because of the growing need to find a valid alternative to BCG for patients with non-muscle invasive bladder cancer (NMIBC).

A group of urologists from Weill Cornell Medicine, New York, NY and Urological Research Network, Miami, FL has presented an interesting pilot study of the feasibility and reproducibility of performing MR/US cryoablation using the MR/US fusion from the Artemis® platform in a step-by-step video at AUA University podcast online.

The great editorial by Dr. Paul Cathcart, a UK expert of salvage robotic radical prostatectomy, has been recently published in the British Journal of Urology International.

We are delighted to announce the WiScope® single-use digital flexible cystoscope, which recently received EU approval and is based on the same imaging platform as a WiScope® single-use flexible digital ureteroscope.

As the global infection rates of COVID-19 continue to rise, investigators in Italy, led by Erika Poggiali, M.D., from Ospedale Guglielmo da Saliceto, evaluated whether lung ultrasound could be an effective tool in also identifying patients who have pneumonia specifically associated with the virus. They published their results in a Letter to the Editor recently in Radiology.

We continue to monitor the COVID-19 outbreak and are adjusting our business practice in line with directives from the BAG and WHO. It is our goal to give ongoing support to our customers while at the same time ensuring the safety and health of our team members.

At the ASCO Genitourinary Cancers Symposium 2020 in San Francisco, Prof. Thomas-Alexander Vögeli from the University Hospital RWTH Aachen, Germany presented very promising results of first two year follow up after the Hyperthermic Intra-VEsical Chemotherapy (HIVEC) with heated mitomycin in a cohort of patients with high risk superficial bladder cancer (TCC).

As 2019 comes to an end, this is our time to say thank you.

Two great papers, recently published in European Urology, confirm that MRI-targeted biopsy is the attractive and reliable diagnostic strategy for prostate cancer compared to the traditional diagnostic pathway of systematic TRUS biopsy.

New strong clinical data for Sonablate HIFU, recently published in the BJU International, confirms very promising medium-term oncological outcomes.

At the AUA congress in Chicago, Prof. Leonard Marks and the UCLA group presented a method for focal HIFU, employing multiparametric magnetic resonance imaging, fusion biopsy, margin generation, and targeted treatment.

We are delighted to announce a new partnership with OTU Medical Inc., a Silicon Valley based medical technology company, which recently received the EU approval for its second generation WiScope® single-use flexible digital ureteroscope.

We’re pleased to announce that the Prostate Imaging and Focal Therapy Masterclass, presented by one of the world’s leading urologists and experts in focal therapy, Prof. Hashim Ahmed, Chair of Urology of Imperial College London, will be returning on the 5-6th April 2019 for its second event.

SonoIQ, a small pocket Ultrasound, transfers high resolution ultrasound images to Android, iOS or Windows smartphone or tablet via WiFi or USB cable.

We are happy to share with you a new study about Gold Anchor from the Karolinska University Hospital in Stockholm, Sweden.
Conclusion of the study: The use of thin needles for the implantation of fiducials appears to reduce the rate of infection despite the use of a single dose of non-broad-spectrum antibiotics as prophylaxis. The marker construct appears to provide stability in the tissues.

The UK urologist group led by University College and Imperial College London published 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate technology of 625 medium to high-risk clinically significant nonmetastatic prostate cancer patients.